Related Experiment Videos
Use of rifampin in Haemophilus influenzae type b infections
Abstract:
Based on evidence that patients with infections due to Haemophilus influenzae type b (HIB) remain colonized after therapy, recommendations for chemoprophylaxis of susceptible contacts have included providing rifampin for patients themselves. However, these recommendations have been made with neither definitive advice concerning the timing of rifampin administration nor any supporting data of efficacy and safety in patients. Our data suggest that rifampin given concurrently with therapeutic antimicrobials is as effective-89% (17/19)--as when given following therapeutic antimicrobials-95% (18/19)--in eradicating pharyngeal HIB. Colonization of the pharynx by HIB was also determined before and during therapy. Almost all patients were colonized before beginning therapy; most were heavily colonized. The density of colonization diminished rapidly during the first 15 to 20 hours of therapy. However, 28% of patients, primarily those who had HIB diseases other than meningitis or did not receive any chloramphenicol, still had detectable colonization after four to six days of antimicrobial therapy.
Insights
Rifampin effectively eradicates Haemophilus influenzae type b (HIB) pharyngeal colonization, whether given during or after standard antimicrobial therapy. This finding supports chemoprophylaxis strategies for HIB infection contacts.
Area of Science:
- Pediatric Infectious Diseases
- Bacteriology
- Antimicrobial Chemotherapy
Background:
- Patients with Haemophilus influenzae type b (HIB) infections often remain colonized post-therapy.
- Current chemoprophylaxis recommendations include rifampin for patients but lack specific timing guidance and efficacy data.
- The optimal timing for rifampin administration in HIB-infected patients is not well-established.
Purpose of the Study:
- To evaluate the efficacy and safety of rifampin for eradicating pharyngeal Haemophilus influenzae type b colonization.
- To compare the effectiveness of concurrent versus sequential rifampin administration with therapeutic antimicrobials.
- To assess the impact of rifampin timing on HIB eradication in infected patients.
Main Methods:
- Prospective study evaluating rifampin administration timing in patients with HIB infections.
- Pharyngeal HIB colonization density was measured before, during, and after antimicrobial therapy.
- Efficacy was assessed by comparing HIB eradication rates for concurrent vs. sequential rifampin administration.
Main Results:
- Rifampin given concurrently with therapeutic antimicrobials achieved an 89% eradication rate.
- Rifampin administered after therapeutic antimicrobials showed a 95% eradication rate.
- Pharyngeal HIB colonization density decreased rapidly within 15-20 hours of therapy, but 28% of patients remained colonized after 4-6 days, particularly those without meningitis or chloramphenicol treatment.
Conclusions:
- Concurrent administration of rifampin with therapeutic antimicrobials is as effective as sequential administration for HIB eradication.
- Rifampin is a safe and effective agent for reducing HIB pharyngeal colonization.
- Further research may be needed to optimize HIB eradication strategies, especially for specific patient subgroups.